|
[PMID]: | 28024943 |
[Au] Autor: | Zhang P; Li CZ; Jiao GM; Zhang JJ; Zhao HP; Yan F; Jia SF; Hu BS; Wu CT |
[Ad] Endereço: | College of Nursing and Rehabilitation, North China University of Science and Technology, Tangshan 063009, Hebei, China. |
[Ti] Título: | Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trials. |
[So] Source: | Eur J Surg Oncol;43(7):1161-1172, 2017 Jul. | [Is] ISSN: | 1532-2157 |
[Cp] País de publicação: | England |
[La] Idioma: | eng |
[Ab] Resumo: | BACKGROUND: The effect of ovarian ablation or suppression (OAS) in premenopausal women with breast cancer is controversial. The overall survival (OS), disease-free survival (DFS) and adverse event of OAS versus no OAS were compared. METHODS: A literature review of EMBASE, Web of Science, PUBMED, and Cochrane Library was conducted. The hazard ratio (HR) and 95% confidence interval (CI) for OS and DFS, as well as risk ratio (RR) and 95% CI for adverse events were evaluated. I-squared statistic (I ) represents heterogeneity. RESULTS: Twenty-nine studies with a total of 21,249 women were included. In premenopausal women aged 40 years or younger, there were significant differences in OS (HR 0.78, 95% CI: 0.66-0.94, P=0.008, I = 0%) and DFS (HR 0.84, 95% CI: 0.73-0.97, P=0.02, I = 0%) between OAS and no OAS. In advanced stage breast cancer, a significant difference was found in OS (HR 0.76, 95% CI: 0.60-0.96, P=0.02, I = 0%). Patients treated with OAS had more chances to have hot flushes (RR 1.91, 95% CI: 1.62-2.26, P < 0.01, I = 0%) and vaginal dryness (RR 1.19, 95% CI: 1.08-1.31, P=0.0003, I = 0%). No significant difference in depression (RR 1.28, 95% CI: 0.94-1.74, P=0.12, I = 0%). CONCLUSIONS: The study shows that OAS plays a beneficial role in premenopausal women aged 40 years or younger and advanced stage breast cancer. However, OAS is associated with increase in hot flushes and vaginal dryness. |
[Mh] Termos MeSH primário: |
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico Neoplasias da Mama/terapia Hormônio Liberador de Gonadotropina/agonistas Ovariectomia
|
[Mh] Termos MeSH secundário: |
Neoplasias da Mama/patologia Terapia Combinada Intervalo Livre de Doença Feminino Gosserrelina/administração & dosagem Gosserrelina/efeitos adversos Seres Humanos Leuprolida/administração & dosagem Leuprolida/efeitos adversos Metástase Linfática Estadiamento de Neoplasias Ovariectomia/efeitos adversos Pré-Menopausa Ensaios Clínicos Controlados Aleatórios como Assunto Taxa de Sobrevida Tamoxifeno/administração & dosagem
|
[Pt] Tipo de publicação: | COMPARATIVE STUDY; JOURNAL ARTICLE; META-ANALYSIS; REVIEW |
[Nm] Nome de substância:
| 094ZI81Y45 (Tamoxifen); 0F65R8P09N (Goserelin); 33515-09-2 (Gonadotropin-Releasing Hormone); EFY6W0M8TG (Leuprolide) |
[Em] Mês de entrada: | 1708 |
[Cu] Atualização por classe: | 170818 |
[Lr] Data última revisão:
| 170818 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 161228 |
[St] Status: | MEDLINE |
|
|
|